← All opportunities

Horizon Europe · European Union

Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment…

Full title in the source: Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Opens 10 Feb 2027

The EU's Horizon Europe programme expects to make 3 awards of €7 million – €9 million each, from a total budget of €24 million. Applications close on 16 Sep 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.

Expected outcome

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities;

• Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation;

• National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems;

Scope

Patients with rare and very rare [2] cancers across EU Member States and Associated Countries often present with advanced disease due to late diagnosis and have access to few treatment options. Hence, these patients typically have a lower 5-year overall survival than those with more common cancers and face challenges with timely access to a small number of appropriate phase 1 clinical trials, despite good disease control rates [3] , to validate biomarker-guided medicines or multi-modal treatment interventions targeting their disease and adapted to an increasingly precision oncology healthcare landscape.

Proposals should address all the following:

• When still relevant and required, finalise the preclinical validation of promising [4] biomarker-guided drugs [5] , for rare or very rare cancer indications through in vivo and/or ex vivo and/or in silico research models. Drug repurposing should be considered [6] . Data should be disaggregated by tumour biology, sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity;

Who can apply

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Applicant categories are a starting point. The official call decides eligibility.

Topics

Anticancer therapy Biophotonics, Imaging, image and data processing Cancer and its biological basis Quality-of-life Radiation therapy Surgery Tomography Clinical Research Common Cancers High Income Countries Oncology Nurses Precision Oncology Tumour Boards Twinning Widening Countries

Timing

Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

How to apply

1. Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
2. Register each participating organisation in the Funding & Tenders Portal to get a PIC.
3. Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
4. Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
5. Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.

From the call text

Who can apply

Not stated in the call text we hold — check the official page

Company stage

Not stated in the call text we hold — check the official page

Single applicant or consortium

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where applicants must be based

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where to apply

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Read the EU application guide

Where these facts come from

Official sources

Official call page

Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.

More from Horizon Europe